Q-omics provides the consensus-scored FOXA3 profile across patient tissues and cancer cell-line models. FOXA3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOXA3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, FOXA3 RNA expression shows 15,031 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, KICH, and ESCA as cancer lineages where FOXA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXA3 survival associations across molecular data types. FOXA3 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXA3 RNA expression–survival associations across cancer types. High FOXA3 expression shows unfavorable associations in ACC, KIRC, KIRP and DLBC, but favorable associations in HNSC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FOXA3 RNA expression.
This table summarizes FOXA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FOXA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXA3 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in LUAD, THCA and UCEC. The KICH box plot shows higher FOXA3 RNA expression in normal versus tumor tissue (log2 FC = −3.302, t-test p < 0.001).
This table shows molecular features associated with FOXA3 in patient tissues and cancer cell lines. In patient samples, FOXA3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
